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The Future
of Abortion
by
Lawrence F. Roberge, M.S.
The author is the author of The Cost of Abortion (Four Winds
Publications, LaGrange, GA, 1995) as well as a biotechnology consultant, college instructor, bioethicist, and biomedical researcher.
He has published research on neuroscience, biomedicine, abortion
vaccine technology, and the adverse effects of abortion on women.

I. Introduction
Is there any surprise at the emotional and political reaction to
President Bill Clinton's veto of the partial birth abortion bill? No?
Yet, perhaps what is surprising is the emotional outcry against this
procedure as compared to the political and social apathy during over
20 years of abortion (within the United States). Why such a reaction
from pro-life and Church leaders now; when the same leaders never
unleashed the same fury and media coverage during the past 23 years
of abortions? Perhaps the answer will yield clues to the future of
abortion in the U.S.
Meanwhile, the availability of abortion clinics and doctors is slowly dwindling. Organized protests at clinics, aoctor's nomes, ami malpractice suits against abortion doctors have contributed to the decline
of abortion service availability. With the decline in available abortion facilities and physicians, how will abortion continue as a method
of eugenics and population control, as well as an erroneously
described "reproductive right"? Perhaps the answer lies in the future
direction of abortion in the U.S.

38

Linacre Quarterly

II. Technology Development
As technological advances in the fields of endocrinology, biotechnology, immunology, and pharmacology progress, the creation of new
abortifacient technologies will continue. Furthermore, these technologies will target the destruction of life at an ever-earlier stage of development. The movement of technologies to destroy life will continue to
focus at the embryonic (up to 2 months of development) stage. This
statement is exemplified by the recent Food and Drug Administration
(FDA) approval of the double-dose birth control pills and FDA market
approval of RU-486 (Mifepristone). The purpose of the double-dose
birth control pill is to block uterine implantation of an early stage
embryo, whereas the progesterone blocking action of RU-486 acts to
terminate embryonic life up to the first 49 days of development.
Beyond these recently approved drugs, the development of other
embryonic stage abortifacients (such as more advanced progesterone
blockers and ETF) is continuing. Furthermore, the development of an
abortifacient vaccine is nearly complete. I•2 This technology does not
block ovulation or conception, but rather blocks embryo implantation
and lead~ to t:'mbryonic death, '.vhich uppeurs as a menstrual peliud.
This technology is targeted for world distribution. The vaccines will
mislead many into believing that they are using a safe, effective form
of birth control, when in reality, the vaccine will engineer a monthly
abortion. The vaccines' effects will last for 18 months.
The early embryo destructive effect on many of these products
brings us to the next clue to the future of abortion.

III. Moving Away From Fetal Death
Advances in technology will reduce the fetal body count while
vastly increasing the embryonic fatalities. As a consequence, this
may increase societal acceptance of abortion. How?
The abortifacient technologies will destroy life at an earlier stage.
Market studies for RU-486 3 alone claim that the product could capture up to 60% of the clinical surgical abortions in the U.S. Other
technologies could surpass that figure.
Furthermore, one method that pro-life uses to convey the humanity
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or "humanness" of the fetus is to display graphic photos of fetuses
with well-formed fingers, eyes, hands, toes, a heart beating, etc.
Advanced abortifacient technologies act to destroy the life in the
embryonic (e.g. trophoblastic) stage well before toes, eyes, hands,
etc., are formed. Also, it will be harder to emotionally associate with
a "hollow ball of cells" (as in the case of the trophoblastic embryo)
than with a human-shaped fetus. In essence, the myth that abortion
just removes a "blob of cells or tissue" will be reinforced.
Even now, the beginning of life is being redefined at the uterine
implantation stage (aka nidation), rather than conception. This redefinition allows justification for such medical activities as human
embryo experimentation and the recently publicized incident in
Britain of the disposal of thousands of human embryos. This redefinition has been supported by the National Institute of Health (NIH)
and the American Fertility Society (AFS).4.5
This new redefining of the pre-embryo as not totally human life
affords not merely research on human embryos, but expanded use of
abortifacients that destroy early life by killing the pre-embryo or
blocking uterine implantation (Remember: blocking uterine implantation leads to rapid death of the embryo). At present, some forms
of birth control (e.g. Intrauterine Devices [IUD] and some versions
of the birth control pills), already block embryonic implantation into
the uterus.
It must be further noted that as more data arises on the complications due to surgically induced abortions, marketing strategies for
abortifacient products will capitalize on this data as a motivational
factor toward more embryo stage-directed abortifacients. Simply
put, pharmaceutical corporations will use available data on abortion
complications (e.g. abortion and infertility link; abortion and breast
cancer link, etc.) to convince the consumer to use birth control that in
reality is abortifa-cienr-in nature. As the p6pulation of consumers
accepting this technology increases, total surgical abortions will
rapidly decrease, while the total number of abortions will rise exponentially. In reality, the population will increasingly be deceived into
accepting abortifacients as a version of effective birth control.
The shift from surgical abortions to pharmaceutical abortifacients
brings us to the next aspect of the future of abortion.
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IV. Pharmaceutical Abortifacients
The market shift to pharmaceutical abortifacients has some advantages. First, this technology reduces the role of clinics and doctors.
Doctors need not use a clinic to prescribe or dispense pharmaceutical
abortifacients. Rather, doctors may dispense these drugs (or vaccines) in their office and such actions will be protected by doctorpatient confidentiality. Also, as previously noted, increasing dissemination of pharmaceutical abortifacients will lead to a decrease in
surgical abortions. As surgical abortions decrease, this will reduce
abortion clinic revenues. Eventually, the declining revenues may
force many clinics to close. Although some clinics may continue to
exist by virtue of distributing abortifacient drugs, the most cost eff ective measure for physicians (and health care providers like HMOs
and PPOs) will be abortifacient distribution at the physician's office.
This shift in abortion (from surgical means to pharmaceuticals)
will further favor the physician in another way.
One of the strong deterrents for physicians working in the abortions
industry is malpractice suits. In recent years, a combined force of
pro-life advocates and legal professionals have unleashed a torrent of
malpractice suits due to botched abortions. As a result, physician participation in the abortion industry has declined as malpractice suits
and malpractice financial settlements have climbed. As abortifacient
technology favors pharmaceuticals, the resultant legal/financial
responsibility shifts away from the sole physician towards the larger
(and more legally formidable) pharmaceutical corporations. The costs
of malpractice insurance would be comparably lower (by dispensing
abortifacients) even though the physician's participation in abortion
would continue. Malpractice suits would be replaced by drug manufacturer law suits which are more lengthy, costly, and more difficult to
win. Furthermore, recent FDA bias toward RU-486 may require
future lawsuits against this federal agency. Law suits at this level are
even more lengthy and difficult (if not impossible) to win.
The distribution of abortifacients by doctors may make abortion
more palatable to physicians. One case in point, a 1995 Kaiser
Family Foundation survey6 has found that doctors who would not
perform surgical abortions would prescribe the abortifacient drug,
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RU-486. FurtherIBOre, the same survey demonstrated that a majority
of the doctors who do not perform abortions have prescribed the
"morning after pill" for emergency contraception. As more abortifacient products enter the marketplace, physicians (even with their
knowledge base of endocrinology, pharmacology, and gynecology as
well as the understanding of the consequences of the use of abortifacient drugs and vaccines) will increasingly tum to prescribe these
products to terminate early stage pregnancies.
Finally, as abortifacient pharmaceuticals rise to the predominant
form of abortion, another important marketing strategy will eventually influence the future of abortion.
Recently, Americans have enjoyed the non-prescription availability of commonly used pharmaceutical products like Nicorette 1m gum,
Tagamet™, Zantac™, Rogaine™, and Naproxin (aka Alleve™). The
process to move a prescription drug to an over the counter drug status (commonly referred to as Rx-to-OTC conversions) has been
accelerating during this decade. Usually, the motivational factor for
this conversion is the end of the pharmaceutical firm's exclusive
marketing of this product as its patent expires.
At present, the only drugs that the FDA will absolutely not allow
Rx-to-OTC conversions are narcotics. It is conceivable that eventually some abortifacients pharmaceuticals (as their patent comes up to
the expiration date) will become available over the counter. Women
could one day in the near future obtain abortifacients in the discount
drug stores as easily as purchasing aspirin, antacids, panty hose, or
nail polish!

v. Counterstrategies
With the future of abortion being directed towards pharmaceutically-based abnrtifa-cients which target-destroying life-earl-y in develGpment, pro-life advocates will face a series of unique challenges. It
must be noted that along with abortifacient technology developments, society will increasingly challenge the definition of when life
begins. For example, some abortifacient vaccine advocates, including HCG vaccine (i.e. abortifacient vaccine) researcher Dr. G. F.
Talwar1, state that life begins not at conception, but when the embryo
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implants itself into the uterine lining (i.e., nidation).
As these redefinitions of the genesis of life continue, disguised
under the cloak of scientific authority, pro-life advocates must
become scientifically and technologically astute with the technologies and issues at hand. Sadly, one of the ~ritical weaknesses that
many major pro-life groups have is a paucity of scientists and technologically trained staffers proficient in the fields of medicine, pharmacology, embryology, molecular biology, immunology, biotechnology, and biochemistry. Many groups may feebly attempt to occasionally seek out a retired medical advisor, but the true weakness of
pro-life is their absence of a permanent scientific staff. As some
groups continue to chant a pro-life mantra, their absence of a staff
technically aware of the new abortion technologies will only demonstrate how these groups have been poor stewards of the funds they
have been entrusted with by their contributors. In short, as the world
becomes even more complex, pro-life forces must become staffed
with knowledgeable individuals who can decipher, comprehend, and
articulate to the general public which technologies promote a culture
of life and/or a culture of death. To do less, is both financially and
morally wrong!
It must be noted that the Alan Guttmacher Institute is the research
arm of Planned Parenthood. This institute has a PERMANENT staff
of scientists and researchers who actively conduct research and publish their work (much of it advocating abortion and contraceptive
technologies) in peer-reviewed journals, gaining the respect and
attention of the medical and scientific community as well as the
American public at large.
Another weakness within pro-life is the classic conflict between
being pro-life, but condoning contraception. This is interesting as it
was contraception that legally heralded abortion (i.e . Roe v
Wade, 1973) via the Supreme Court decision of GriswoLd V
Connecticut, (1 965). But, beyond legal considerations, many pro-life
advocates still remain silent or in a state of neo-denial over the relationship between contraception and abortion. As contraception
helped to crystallize the concept of "Babies/children can be a burden" in the American psyche, abortion became the accepted means to
deal with the "problem". In short, abortion followed as a "solution"
to the "problem" of pregnancy.
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Despite medical and pharmaceutical data going back to the 1960s
demonstrating that certain forms of birth control (e.g. birth control
pills) did in fact induce a very early stage abortion (example: via
blocking the implantation of the embryo into the uteririe lining), some
elements of the pro-life community have remained silent, choosing
rather to focus on fetal surgical abortions. With this continued schizophrenic mentality, these pro-life elements will become effectively shut
out (and silenced) in the abortion debate, as the future of abortion progresses towards pharmaceutical early stage techniques. In essence, as
the world is being told that the new abortifacients are just "birth control"; and as the beginning of life is reclassified at nidation, not conception; then the pro-contraception pro-life forces will, by default,
surrender and become silent in the debate. Meanwhile, more lives
will be lost amidst the silence over these technologies.
The counterstrategy to this scenario may require vigorous education on two fronts. First, reeducation and active discussion to break
the myth that life begins some time AFTER conception. Second, discussion on the real connection between contraception and abortion.
Finally, a sad but real third possible strategy includes public exposure of the "Fifth Column" pro-life organizations or leaders that quietly accept future abortifacient "contraception". This strategy is
admittedly painful and publicly unpleasant, but in the future, it may
be required. As some physicians and therapists have pointed out,
"The first step to healing the patient is admitting or identifying the
ailment in question."

Conclusions
The future of abortion is a future which will involve technologies
that destroy life at a much earlier stage of development. As such, it
will increase public acceptance ofa bortion;reduce the overaH costs
to pro-abortion facilities; reduce reproductive responsibility; and
mute much of the societal emotional response to those destroyed in
the womb. Pro-life will face a plethora of new technologies. These
technologies will increase the abortion casualty numbers, increase
abortion access, and reduce the educational opportunities to the general public.
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The response to the future of abortion is two-fold. The challenge
to pro-life will require the acquisition of scientific and technological
staffers who can comprehend and educate the public on these technologies and their consequences.
Furthermore, a reexamination of the connection between contraception and abortion is required. The strong wall separating these
two concepts must be pulled down and the public must be thoroughly
educated on the close ties between abortion and contraception - both
psychologically and technologically. Those pro-life forces that fail
to do this may be faced with a future of obsolescence.
Finally, should pro-life forces fail to warn society about the future
of abortion and its implications, American society itself may eventually be faced with obsolescence.
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